Kristen Oelschlager Sells 12,218 Shares of Castle Biosciences (NASDAQ:CSTL) Stock

Posted by Geri Gentry on Aug 26th, 2026

Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) COO Kristen Oelschlager sold 12,218 shares of the firm’s stock in a transaction dated Monday, August 24th. The shares were sold at an average price of $33.69, for a total value of $411,624.42. Following the completion of the sale, the chief operating officer owned 85,033 shares of the company’s stock, valued at approximately $2,864,761.77. This represents a 12.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Castle Biosciences Stock Down 2.6%

CSTL stock traded down $0.92 during trading on Wednesday, reaching $34.08. 456,261 shares of the stock were exchanged, compared to its average volume of 406,528. The firm’s 50 day moving average is $26.45 and its 200 day moving average is $25.39. The firm has a market cap of $1.04 billion, a P/E ratio of -51.64 and a beta of 0.98. The company has a current ratio of 6.04, a quick ratio of 5.85 and a debt-to-equity ratio of 0.02. Castle Biosciences, Inc. has a twelve month low of $17.72 and a twelve month high of $44.28.

Castle Biosciences (NASDAQ:CSTL – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, beating the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The firm had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. As a group, research analysts forecast that Castle Biosciences, Inc. will post -1.29 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently commented on the stock. Roth Capital assumed coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 target price for the company. Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, May 26th. BTIG Research boosted their price objective on Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a report on Monday, August 3rd. KeyCorp set a $35.00 price objective on Castle Biosciences in a research note on Friday, May 29th. Finally, Robert W. Baird set a $36.00 target price on Castle Biosciences in a report on Friday, July 31st. One equities research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Castle Biosciences has a consensus rating of “Moderate Buy” and an average target price of $42.00.

Check Out Our Latest Stock Report on CSTL

Institutional Trading of Castle Biosciences

Institutional investors and hedge funds have recently modified their holdings of the business. Amundi boosted its position in Castle Biosciences by 15,811.5% in the first quarter. Amundi now owns 4,137 shares of the company’s stock worth $79,000 after purchasing an additional 4,111 shares during the last quarter. AQR Capital Management LLC raised its stake in shares of Castle Biosciences by 548.9% during the 1st quarter. AQR Capital Management LLC now owns 137,022 shares of the company’s stock worth $2,743,000 after purchasing an additional 115,907 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Castle Biosciences by 4.4% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,441 shares of the company’s stock worth $309,000 after purchasing an additional 655 shares during the period. Jones Financial Companies Lllp boosted its holdings in shares of Castle Biosciences by 10,592.0% in the 1st quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock worth $54,000 after buying an additional 2,648 shares during the last quarter. Finally, Legal & General Group Plc boosted its holdings in shares of Castle Biosciences by 34.7% in the 2nd quarter. Legal & General Group Plc now owns 34,908 shares of the company’s stock worth $713,000 after buying an additional 8,992 shares during the last quarter. 92.60% of the stock is owned by hedge funds and other institutional investors.

About Castle Biosciences

(Get Free Report)

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.